Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Intensified Decitabine in Relapsed/Refractory AML (VenSwitch)
NCT06156579Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University Hospital Tübingen. Started Nov 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06156579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156579.